Beyond distribution, Kysmaq offers a full-service platform for foreign medical companies aiming to enter the Japanese market. We support:

• Access to our PMDA license for registration
• Guidance on reimbursement and pricing strategy
• Distributor matching or setting up direct sales teams
• Full regulatory and cultural support through local operations

Thanks to our international expertise (US, Europe, Middle East, China/Asia) and our deep understanding of Japanese business practices, we are uniquely positioned to offer a trusted and efficient route to market.

If your company is planning to enter Japan, we invite you to collaborate with us for a transparent, fast, and secure launch.

We have established a strategic partnership with leading Japanese dealer ITI, expanding our reach and strengthening product support across Japan. This cooperation allows us to deliver high-quality technologies with excellent field service and national coverage.

We are now offering Class I certified surgical loupes and Infab radiation protection equipment, providing comfort, accuracy, and safety for:

• Surgeons

• Dentists 

• Operating room staff

• Aesthetic and beauty professionals

Pre-orders and demo requests are now open for clinics and hospitals.

Kysmaq is proud to have signed a strategic distribution agreement with Lexion Medical, a U.S.-based leader in gas conditioning and smoke evacuation systems for laparoscopic and robotic surgery. While Lexion’s products are not yet registered in Japan, Kysmaq is actively preparing for registration and market entry.

Lexion’s innovative solutions include:

• AP 50/30 Insufflator – High-performance pneumoperitoneum management

• InsuflowPort® – Advanced gas conditioning access port

• PneuView Smoke Eliminator – Clear visualization during surgery

We are now engaging with select hospitals and surgeons interested in learning more about Lexion’s offering and participating in early-stage evaluations. Please contact us to register your interest.

Kysmaq continues to grow the Japanese market for Memokath stents. These minimally invasive solutions are ideal for elderly and frail patients, offering an alternative to surgery:

• MK028 and MK044 are already used in hospitals and clinics across Japan

• MK045 (bladder neck stent) – expected launch in ~3 months

• MK051 (ureteric stent) – expected launch in ~6 months

We welcome early adopters, doctors, and hospitals to express interest in these upcoming products or request clinical discussions with our team.

Since May 2024, Kysmaq has been led by CEO Casper Saxenfelt Tvede, a Danish executive with over 25 years of experience in the global medtech industry. Under his leadership, Kysmaq is shaping a new direction: becoming the most trusted partner in urology, minimally invasive surgery, and market access for international medical device companies in Japan.